How to Choose Osteoporosis Medicine
For women with known osteoporosis, start with oral alendronate, risedronate, or if gastrointestinal intolerance or very high fracture risk exists, use zoledronic acid or denosumab as first-line therapy. 1
Risk Stratification Determines Drug Selection
The choice of osteoporosis medication fundamentally depends on categorizing patients into high risk versus very high risk for fracture:
High Risk Patients
- T-score ≤ -2.5 at spine, hip, or femoral neck
- 10-year FRAX major osteoporotic fracture risk ≥20% OR hip fracture risk ≥3%
- History of low-trauma fracture
Very High Risk Patients
- Recent fracture (within 12 months)
- Multiple vertebral fractures
- Fractures while on osteoporosis therapy
- Very low T-score (< -3.0)
- High fall risk or history of injurious falls
- Very high FRAX scores (major osteoporotic fracture >30%, hip fracture >4.5%)
First-Line Medication Selection Algorithm
For High Risk Patients (Standard Risk)
Oral bisphosphonates are first-line:
- Alendronate 70 mg weekly OR Risedronate 35 mg weekly or 150 mg monthly
- These are the only agents with proven efficacy reducing hip, vertebral, AND nonvertebral fractures 1, 2
- Use generic formulations when possible for cost-effectiveness 1
Critical administration requirements for oral bisphosphonates:
- Take after overnight fast, first thing in morning
- Swallow with full glass of water
- Remain upright for 30 minutes before eating or taking other medications
- Contraindicated if: esophageal abnormalities, inability to stand/sit upright for 30 minutes, or active upper GI disease 2, 4
For Very High Risk Patients
Anabolic or dual-action agents should be considered as initial therapy:
- Romosozumab (12 monthly injections) followed by antiresorptive
- Teriparatide or Abaloparatide (up to 2 years) followed by antiresorptive
- Zoledronic acid 5 mg IV annually
- Denosumab 60 mg subcutaneously every 6 months
The evidence increasingly supports anabolic-first strategies in very high-risk patients, as teriparatide produces greater BMD increases (7% vs 3.4%) and greater vertebral fracture reduction (6.1% vs 0.6%) compared to alendronate in high-risk populations 2.
Special Circumstance Modifications
Gastrointestinal Intolerance
If oral bisphosphonates cause upper GI symptoms:
- Switch to IV zoledronic acid (5 mg annually) - bypasses GI tract entirely 1, 2
- Denosumab (60 mg SC every 6 months) - alternative injectable 1, 2
- Consider anabolic agents if very high risk
Renal Impairment
Critical consideration: eGFR thresholds
- eGFR ≥30 mL/min/1.73m²: Oral bisphosphonates (alendronate, risedronate) are safe 6, 7
- eGFR <30 mL/min/1.73m²:
- Denosumab is preferred - no dose adjustment needed, but monitor calcium closely and ensure adequate vitamin D 2, 6
- Bisphosphonates traditionally contraindicated, though post-hoc analyses suggest risedronate may be safe with strict monitoring 7
- Zoledronic acid contraindicated if eGFR <35 mL/min/1.73m² 8
Younger Postmenopausal Women (Vertebral Fracture Risk Only)
- Raloxifene 60 mg daily may be appropriate if:
Contraindication: History of or risk for venous thromboembolism, stroke, or cardiovascular events 1
Men with Osteoporosis
- Bisphosphonates (alendronate, risedronate, zoledronic acid) reduce vertebral fractures 1
- Evidence is weaker than for women but supports same first-line approach 1
Critical Pitfalls and Sequencing Rules
Denosumab-Specific Warning
Never stop denosumab without transition therapy. Discontinuation causes rapid bone loss and rebound multiple vertebral fractures. Must transition to bisphosphonate (typically zoledronic acid or high-dose oral bisphosphonate) 5, 9
Post-Anabolic Therapy
Always follow teriparatide, abaloparatide, or romosozumab with antiresorptive therapy (typically alendronate or zoledronic acid) to maintain BMD gains 5, 2, 10
Bisphosphonate Holidays
After 5 years of oral bisphosphonates or 3 years of IV zoledronic acid, consider drug holiday in patients who:
- Have stable/improved BMD
- No new fractures
- Are no longer at very high risk
Do NOT give drug holidays with denosumab - effects reverse rapidly after 6 months 2, 5
Monitoring During Treatment
- Do NOT routinely monitor BMD during first 5 years of bisphosphonate therapy 1
- Reassess fracture risk yearly, particularly in very high-risk patients 2
- Consider bone turnover markers to assess adherence and response 3